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To the Editor:
My paper: A neural model for chronic pain and pain relief
by extracorporeal shock wave treatment (Urol Res (2008)
36:327–334) [1] provoked a vigorous offence by Ch.
Schmitz and DePace (Letter to the Editor: Pain relief by
extracorporeal shockwave therapy: an update on current
understanding, Urol Res (2009) 37:231–234) [2] which
requires a clarifying reply.
What is the concept and content of the neural model
presented?
The original paper outlines a new concept of chronic pain
on the basis of neural pain memory. The basic idea is the
establishment of ‘‘pathologic’’ reﬂex patterns linking sen-
sory input with motor output nerve signals during chroni-
ﬁcation of pain sensation. The neurological mechanism
behind is hypothesized to be based on the plasticity of
synaptic junctions. The working mechanism of shock wave
therapy is hypothesized to erase the ‘‘pathologic’’ links
between sensory input and motor output by hyper stimu-
lation through shock wave stimuli (for details see original
paper).
Presenting a hypothesis as published enables the scien-
tiﬁc community to test the hypothesis against real biolog-
ical ﬁndings. Scientiﬁc hypotheses in general need to be
detailed and substantiated to enable basic tests for possible
falsiﬁcation, whereas a general veriﬁcation is impossible,
see e.g., Popper [3]. Nevertheless, a detailed and substan-
tiated hypothesis/theory is of high value providing a basis
for realistic predictions which, according to experience,
come true as long as attempts for falsiﬁcation are not
successful (Popper, ibid.). The purpose of my paper is to
present a new model of chronic pain in general and of
chronic pelvic pain (CPP), in particular, as well as devel-
oping a possible neural working mechanism of shock wave
therapy. The hypothesis is based on the neural functions of
the brain and is open for critical review and substantiated
attempts of falsiﬁcation. This is a widely accepted scien-
tiﬁc method to achieve objective knowledge of empirical
sciences (see Popper, ibid.) at least the method I prefer.
What is the concept and content of the Letter
of Schmitz and DePace?
First of all I wonder why the Letter to the Editor was
published since it does not focus on the matter of my
hypothesis at all but presents offending speculations of
questioning my competence and earnestness to publish a
scientiﬁc hypothesis. Instead, Schmitz and DePace take the
opportunity to elaborate on a separate subject of molecular
mechanisms of ESWT, a ﬁeld, one of the authors, Schmitz,
has worked upon. Molecular mechanisms are the physio-
logical substructure of biological functions including neu-
ral activities but are not the subject of the original paper.
Neither the presented claims, papers and personal specu-
lations are focused on substantial details of my hypothesis
nor could I come to the realization that any attempt has
been made to falsify my hypothesis, in order to be a decent
scientiﬁc approach.
The authors, however, exhibit personal critics on my
paper mainly in four different aspects (see below) in an
apparent expert manner including imputations with respect
to an unfair and hidden motivation due to my afﬁliation
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Since it had been published, I will brieﬂy comment on this:
1. A warning to apply shock wave therapy to indications
such as chronic pelvic pain and angina pectoris ‘‘We
believe, a clear warning should be expressed to your
readership (…) p. 231, 1st column, lines 9–10 (…)
chronic pelvic pain syndrome or angina pectoris can be
regarded only experimentally to date (…) or for that
matter, anecdotally. The casual use of ESWT in the
treatment of angina pectoris could result in unwanted
side effects such as embolism or even severe damage
of lung.’’ p. 231, 1st column, lines 22 ff.
2. Refusal of the involvement of higher levels of the
central (CNS) and peripheral nervous system (PNS)
‘‘ESWT is not used in the international peer-reviewed
literature to treat pain without underlying anatomical
disorders (original paper), and ESWT cannot be
regarded no more focused on speciﬁc organs under
pain but on pain memory (original paper)’’.
3. Neglect of relevant literature ‘‘Our major concern,
however, is linked to Section Associative memory
model for establishing reﬂex functions (original paper)
of Dr. Wess’ article. This section outlines in one and
half pages, a hypothesis of so-called associative pain
memory, without so much as a reference to the
literature’’ p. 231, 2nd column, lines 2–7.
4. Imputation of hidden motivation ‘‘One can only
speculate as to Dr. Wess’ motivation to publish his
hypothesis (…).’’ ‘‘An interesting indication in this
regard might emerge from the fact that Dr. Wess is
afﬁliated with Storz Medical AG (Ta ¨gerwilen, Swit-
zerland), the manufacturer of several shock wave
systems (among them the D-ACTOR 200 marketed in
the USA (…). The Food and Drug Administration
(FDA) classiﬁes extracorporeal shock wave devices as
Class III, higher risk devices’’, p. 232. 2nd column,
lines 37–48. ‘‘In contrast, the extracorporeal shock
wave system D-ACTOR 200 has been presented to
FDA as Class I medical device’’, p. 233, 1st column,
lines 32–34.
Response to 1 The medical indications chronic pelvic
pain syndrome (CPPS) or angina pectoris (as well as oth-
ers) are, in fact, clinically used and taken as an example for
the surprisingly wide variety of successful application of
extracorporeal shock wave therapy (ESWT). They are used
as introduction into the subject of my paper for clariﬁcation
of the wide impact of ESWT, not limited to a single spe-
ciﬁc disease. The purpose of the paper is not developing
‘‘guidelines for the application of ESWT’’ but to refer to
medical facts. Meanwhile, there are several prospective,
randomized, double-blinded controlled studies supporting
safety and efﬁcacy of the mentioned indications [4, 5].
Both, CPPS and Angina pectoris (as well as others), are
cleared by European Authorities (CE-Mark) for speciﬁc
shock wave devices such as the DUOLITH SD1 and the
MODULITH SLC from Storz Medical AG. (Both devices
are considered ‘‘shock wave devices’’ in a physical sense of
the term ‘‘shock waves’’ whereas this does not apply to the
D-ACTOR 200.) Since any therapeutic procedure needs to
be performed by medical personnel in a professional
manner, a speciﬁc warning imputes an unjustiﬁable and
careless behavior of the author of the original paper which
is inappropriate.
Response to 2 Schmitz and DePace oppose against the
term: pain without underlying anatomical disorders (ori-
ginal paper) and replace it by ‘‘anatomically deﬁned’’
diseases (p. 232 left column, lines 3 and 30). If we consider
chronic pain without underlying anatomical disorders,w e
will exclude pain diseases due to acute injuries or other
persistent local reasons such as tumors or acute external
stimuli such as excessive heat, cold, electrical, mechanical
or chemical and other pain generating stimuli. Chronic pain
is understood as pain no longer acutely caused by one of
the mentioned reasons. There are several chronic pain
diseases no longer maintained by acute injuries or external
pain generating stimuli (which often have been the original
cause or trigger of pain during the acute phase), but which
persist for a long period of time after the initial injury or
the stimulus has been dissolved.
The European Association of Urology (EAU) deﬁnes
chronic pain (in relation, e.g., to CPPS) as follows [6]:
Acute or chronic pain Pain may also be described as
either acute or chronic pain:
• Acute pathological pain has an acute onset and is short-
lived, usually less than 1 week or so, and is associated
with tissue trauma, e.g., following surgery. Transient
acute pain may also be caused by acute nerve injury,
e.g., local injury to the ulnar nerve from hitting the
elbow. Although the mechanisms of acute and chronic
pain may overlap, the mechanisms of acute pain resolve
quickly in contrast to chronic pain.
• Chronic (also known as persistent) pain occurs for at
least 3 months. However, the mechanisms involved are
more important than the duration of the pain. Chronic
pain is associated with changes in the central nervous
system (CNS), which may maintain the perception of
pain in the absence of acute injury. These changes may
also magnify perception so that non-painful stimuli are
perceived as painful (allodynia), while painful stimuli
are perceived as more painful than expected (hyperal-
gesia). The bladder provides a good example of how
changes in the CNS affect sensory perception. An acute
pain insult to the bladder can produce functional
changes within the CNS, so that pain persists even
516 Urol Res (2011) 39:515–519
123after removal of the stimulus. These central functional
changes may also be associated with a dysaesthetic
(unpleasant sensation) response; for instance, mild
distension or stimulation of the bladder by urine not
normally perceived may produce the urge to urinate.
Furthermore, core muscles, including pelvic muscles,
may become hyperalgesic with multiple trigger points,
while other organs may also become sensitive, e.g., the
uterus with dyspareunia and dysmenorrhea, the bowel
with irritable bowel symptoms. The spread of abnormal
sensory responses between the organs and musculo-
skeletal system is a well-described consequence of the
CNS changes and a crucial cause of complex chronic
pelvic pains. Functional abnormalities such as urinary
retention may also occur. Chronic pain is associated
with various psychological responses, partly due to the
long duration of the pain and partly due to neuroplas-
ticity of the CNS. Chronic pain inhibits feelings,
emotions, thinking and reactions, while reduced mobil-
ity and inhibited physiological functions restrict social
interactions and work. Although there are established
management strategies, pain is often undertreated
because many clinicians have a poor understanding of
the principles of pain therapy. Efforts are needed to
improve this situation. When appropriate, management
should be both holistic and multidisciplinary.
Often muscle and vessel spasms are associated with
chronic pain resulting in reduced circulation and malnu-
trition of the affected organ as outlined. In consequence to
persistent malnutrition and reduced circulation, however,
impairment of organ functions may occur later.
The involvement of the central nervous system in the
development of chronic pain is recognized by several
authors [7–9] and can be considered state of the art. The
presented hypothesis of associative pain memory is based
on these general ideas. It does not only focus on local
biochemical effects but, complementary, on higher levels
of the peripheral and central nervous system. The innova-
tive part of the hypothesis is the proposed working mech-
anism of chroniﬁcation as outlined on the basis of a
holographic brain model in some detail which, in turn,
offers a new hypothesis for the working mechanism of
ESWT for pain relief. This is the purpose of the original
paper as outlined. To avoid further misinterpretations, I
would like to remind the reader of the original paper: Shock
waves are applied extracorporeally, by coupling the ther-
apy head of the device to the painful area [original paper,
p. 328, 1st Column, lines 4–6)]. The term no more focused
on speciﬁc organs under pain but on pain memory (original
paper) does not stand for a direct exposure of shock waves
to the brain but to the end organ itself, activating the
speciﬁc (organ related) sensory and motor nervous
pathways to and from the brain to the organ under treat-
ment. Insofar, the therapeutic approach, according to the
pain memory concept, is no more focused on speciﬁc
organs under pain but on pain memory (original paper).
Finally, I do not deny molecular mechanisms at the end
organ triggered by ESWT (mechano-transduction). But that
is not the issue of my paper. On the contrary, the painful
shock wave impact results in generation of strong neural
action potentials which are traveling from the impact area
to higher levels of the CNS. This type of mechano-sensory
transduction is considered to be a prerequisite for ESWT
affecting pain memory. This, in turn, could be an expla-
nation for the reduced effect of ESWT when applied under
local anesthesia, since strong nerve signals are blocked and
cannot reach higher levels of the CNS.
As outlined above, the unquestioned involvement of
molecular mechanisms does not exclude memory mecha-
nisms of the CNS and they are not sufﬁcient enough to
understand chronic pain and pain relief by ESWT. There-
fore, restriction to molecular mechanisms only, cannot be
seen as an update on current understanding but rather a step
backwards.
Response to 3 Memorizing, the subject of the original
paper outlines ‘‘A neural model for chronic pain and pain
relief by extracorporeal shock wave treatment’’. Accord-
ingly, references 12–25 (see original paper) relating to the
most relevant publications with respect to the outlined
neural model are cited.
Schmitz and DePace, however, criticise for not quoting
their own and other papers regarding to local mechanisms
of liberation of biochemical drugs and their inﬂuence on
the healing process initiated by ESWT. The list of literature
presented in the Letter by Schmitz and DePace is neither
neglected nor considered to be irrelevant. Citations 1–11 of
the original paper related to the local (biochemical) effects
published by several authors in an exemplary manner,
without focussing explicitly on the papers listing Schmitz
as co-author.
I am well aware of shock wave effects at the end organ
such as liberation of nitric oxides (NO), vascular endothelial
growth factors (VEGF) [10], substance P [11] and others.
Temporary increase in circulation and metabolism is rec-
ognized. Relief of chronic pain, however, cannot be solely
restricted to biochemistry mechanisms at the end organ by
dogmatic insistence on molecular mechanisms as published
bySchmitzetal.ThereportedliberationofsubstanceP,e.g.,
does not falsify my hypothesis of shock wave interaction
with pain memory, however, supports the idea. In my opin-
ion, permanent healing of chronic pain diseases is better
understood by taking additional (complementary) mecha-
nisms into account, affecting chronic pain memory as, e.g.,
elaborated and published in the original paper.
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molecular model of pain relief, being exclusively the one
and only, there is no scientiﬁc reason to disclaim alterna-
tive concepts as long as they could not falsify them.
Response to 4 It appears to be the main issue for
Schmitz and DePace to exclude a competitive product
(D-ACTOR 200, Storz Medical) from the American market
by claiming the D-ACTOR 200 being incorrectly presented
to the FDA. ‘‘Dr. Wess’ hypothesis (…) should be evalu-
ated cautiously against the fact that the extracorporeal
shock wave system D-ACTOR 200 manufactured by Storz
Medical AG (Dr. Wess’ afﬁliation) has not been presented
to FDA as a Class III extracorporeal shock wave device
(…)’’. In other words, The D-ACTOR 200 is claimed to be
an unproven extracorporeal shock wave device, which
would require an IDE study according to a correct classi-
ﬁcation (Class III) same as the competing DolorClast by
EMS.
With these statements, Schmitz and DePace introduce
marketing aspects which have nothing to do with my
hypothesis.
It does not become apparent to me why Schmitz and
DePace link my hypothesis to the product classiﬁcation
according to the American Food and Drug Administration
(FDA). FDA’s criteria for market clearance of medical
products in the US are ‘‘safety and efﬁcacy’’. Up to my
knowledge, there is no reason why my hypothesis has any
impact on the FDA’s judgment regarding either one of the
two criteria or why it should have any impact on the market
clearance of the D-ACTOR 200 in the US. Moreover, the
hypothesis was orally presented at several congresses as
early as 2001 (Mainz) [12], 2004 (Kaoshiung) [13]), 2005
(Vancouver) [14], years before the D-ACTOR 200, was
introduced in the market in 2008. Schmitz and DePace
impute the classiﬁcation issue being the hidden motivation
of my hypothesis. I forcefully reject this unfounded
speculation.
Schmitz and DePace complain about the D-ACTOR 200
not being classiﬁed as (orthopedic) ‘‘extracorporeal shock
wave device’’ (Class III), whereas the Swiss DolorClast
(EMS Electro Medical Systems, Nyon Switzerland) the
company, Schmitz and DePace have been afﬁliated with,
was classiﬁed Class III (requiring an extensive and costly
IDE study). There is a simple reason: the D-ACTOR 200 is
not a shock wave device in the physical sense. This holds
also true for the DolorClast of EMS [15] which is sub-
stantially equivalent to the D-Actor 200 even if it had been
presented to FDA as Class III device. According to the
clearance issues, it makes a crucial difference with respect
to market access, notably in the US.
One should keep in mind that the D-ACTOR 200 was
not mentioned in my original paper at all and was no
subject thereof. If at all, speciﬁc shock wave devices in a
physical sense such as the DUOLITH SD1 and the
MODULITH SLC of Storz Medical AG may be mentioned
in this regard.
The background of my hypothesis roots back to the late
1990s (ﬁrst presented in 2001) and is based on the concept
of a holographic brain model published in the 1970s by
myself and other authors (see references 1–12 of the ori-
ginal paper).
Finally, Schmitz and DePace express a warning against
my hypothesis without any falsiﬁcation thereof and stoke
fears regarding the safety of the D-Actor device:
‘‘Dr. Wess’ hypothesis (…) should be evaluated cau-
tiously against the fact that the extracorporeal shock wave
system D-ACTOR 200 manufactured by Storz Medical AG
(Dr. Wess’ afﬁliation) has not been presented to FDA as a
Class III extracorporeal shock wave device but rather as
Class I device, being similar in function and purpose to
Therapeutic Massagers.’’
Schmitz and DePace do not only ignore the fact that the
D-Actor 200 is not a shock wave device (as well as the
EMS Dolorclast, see above), but also impute a possible risk
of the device without providing any reason whatsoever.
FDA’s classiﬁcation, however, cannot be taken for proof:
since ﬁrstly, the D-ACTOR is not a shock wave device as
mentioned and secondly, not every shock wave device is
classiﬁed Class III by the FDA. Shock wave lithotripsy
devices cleared for use in urology (kidneys stone litho-
tripter) are classiﬁed Class II although exposing well-per-
fused kidney tissue with approximately ten times higher
shock wave energy as speciﬁc ‘‘orthopedic shock wave
lithotripters’’ which are classiﬁed Class III. The inconsis-
tent use of the term ‘‘shock waved device’’ by FDA does
not qualify a ‘‘none shock wave device’’ as a real
‘‘shockwave device’’. FDA, although being an US-gov-
ernmental institution, is not to be acknowledged as the
authority for standardization such as the National Institute
of Standards and Technology (NIST) and cannot deﬁne
ordinary pressure waves (as used by the EMS Dolorclast
and the Storz Medical D-Actor) as ‘‘shock waves’’ in a
physical sense. The Urological Research Journal might not
the right place to discuss these market clearance issues.
However, they were brought up by the Letter of Schmitz
and DePace and requested a response.
Conclusion
The Letter to the Editor of Schmitz and DePace did not do
justice to the issue of my original paper.
It is to be hoped that my hypothesis gets a fair chance to
be critically reviewed by the scientiﬁc community. The
hypothesis does not deserve a disparaging attack based on
the competition and marketing issues. Critical and detailed
518 Urol Res (2011) 39:515–519
123evaluation of the hypothesis presented may not only guide
the way for a better understanding of chronic pain phe-
nomena but may also develop a basis for better treatment
options of CPPS and other chronic pain diseases.
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